Page last updated: 2024-12-07

ips 339

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

IPS 339: RN refers to mono-HCl without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121847
CHEMBL ID3276768
MeSH IDM0063763

Synonyms (9)

Synonym
9h-fluoren-9-one, o-(3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)oxime, monohydrochloride
ips-339
ips 339
60979-28-4
(t-butyl-3-amino-2-propanol)-9-oximinofluorene hydrochloride
CHEMBL3276768
DTXSID80976456
1-(tert-butylamino)-3-{[(9h-fluoren-9-ylidene)amino]oxy}propan-2-ol--hydrogen chloride (1/1)
1-(tert-butylamino)-3-(fluoren-9-ylideneamino)oxypropan-2-ol;hydrochloride

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Thus, for determination of administration frequency and dosage of beta-adrenoceptor blocking drugs, not only pharmacokinetic but also pharmacological data (duration of action) are essential."( Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.
Himori, N; Honma, S; Ishimori, T; Izumi, A, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1146344Antagonist activity at beta-1 adrenergic receptor in spontaneously beating guinea pig right atrium assessed as inhibition of isoprenaline-induced positive chronotropic effect preincubated for 30 mins followed by isoprenaline challenge in presence of ascor1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers.
AID1146352Antihypertensive activity in spontaneously hypertensive rat model1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers.
AID1146348Selectivity ratio for in vivo inhibition of beta-2 adrenergic receptor in Mongrel dog over in vivo inhibition of beta-1 adrenergic receptor in Mongrel dog1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers.
AID1146346Selectivity ratio of antagonist activity at beta-2 adrenergic receptor in carbachol-treated guinea pig trachea to antagonist activity at beta-1 adrenergic receptor in spontaneously beating guinea pig right atrium1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers.
AID1146345Antagonist activity at beta-2 adrenergic receptor in carbachol-treated guinea pig trachea assessed as inhibition of isoprenaline-induced contraction preincubated for 60 mins followed by isoprenaline challenge in presence of ascorbic acid and phentolamine1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers.
AID1146347Selectivity ratio for in vivo inhibition of beta-2 adrenergic receptor in guinea pig over in vivo inhibition of beta-1 adrenergic receptor in guinea pig1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers.
AID1146351Toxicity in spontaneously hypertensive rat model assessed as increase in blood pressure1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (92.31)18.7374
1990's2 (7.69)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.16 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]